<span>Animal Health: Veterinary Vaccine Development</span>
April 29, 2025

Animal Health: Veterinary Vaccine Development

Streamline vaccine development with operational efficiency and flexible study design Veterinary vaccine development is crucial for animal health, public safety and food security by helping to prevent zoonotic diseases, reduce antibiotic use and protect livestock productivity. However, challenges like disease variations, regulatory hurdles, high costs, cold chain logistics, species-specific efficacy and public reluctance hinder widespread adoption.
<span>Extraction Vehicle Selection for the Material Mediated Pyrogen Test</span>
April 29, 2025

Extraction Vehicle Selection for the Material Mediated Pyrogen Test

Following submission of a package to a regulatory body, it is typical to receive feedback regarding some portion of the submission, including biocompatibility. Recently, Labcorp provided guidance to a client who needed help responding to a submission finding that we had previously navigated. We share both the finding and response below. Sharing common or important findings, and the responses to them, can help the community and regulators better understand the evaluation methods and ensure that future submissions are as successful as possible.
<span>Site neutrality and future-proofing the laboratory</span>
April 29, 2025

Site neutrality and future-proofing the laboratory

Bryan Vaughn, senior vice president of health systems at Labcorp, shares his perspective on site neutrality and how to future-proof the lab. For health system leaders, early 2025 has been a whirlwind of potential policy changes – from Medicaid funding to NIH grants – that could impact providers in a material, long-term manner.  Underlying and apart from policy uncertainty, 2025 could well be an inflection point for healthcare costs.  
May 11, 2025

OECD bumblebees with dimethoate and future alternatives

SETAC Europe 2025 -- Assessing the acute toxicity of pesticides on non-target species, particularly bees, is essential for evaluating environmental risks. The absence of defined concentration ranges and shorter time endpoints in bumblebee tests limits precise health assessments and control chart establishment.

April 29, 2025

Labcorp Announces 2025 First Quarter Results

Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: